• Tue news: Merck's Keytruda stages comeback in head and neck cancer. GSK, Pfizer RSV vaccine sales fall. Astellas gene therapy bet. Extreme weather —>drug shortages. J&J discontinues bladder cancer drug. See more on our front page

The stock price

Couldn’t hold over $30 after ex-dividend. Couldn’t trend from the quarterly beat. Can’t articulate a strategy or rationale for ditching the scientific officer or marketing officer.
In other words, no clarity, no plan and no way to explain why we are below the stock price of a decade ago. It’s time for the Veterinarian and Helpful Hardware man to set up their respective shops in some strip center off the Jersey Turnpike. Less than sideways after a decade is no way to run a publicly held company.
We didn't need to hear a rationale for the ditching of the last marketing officer. We needed a rationale for hiring and allowing him to do what he did. I mean, goodness sake, what a mess!
 




Similar threads

Replies
1
Views
843
Pfizer
anonymous
Replies
36
Views
4K
Pfizer
anonymous
Replies
8
Views
2K
Pfizer
anonymous
Replies
5
Views
2K
Pfizer
anonymous
Replies
13
Views
2K
Pfizer
Anonymous